Thomas G. Martin, III, MD, Krina Patel, MD, MSc - Hitting the BCMA Target in Multiple Myeloma: Insights on CAR-T Therapy and Innovative Antibody Options

Go online to PeerView.com/FNM860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Find out if you are updated on the latest evidence and
management considerations on the use of BCMA antibodies and CAR-T
cell therapy for the management of multiple myeloma (MM) in this
new PeerView learning CME video recorded at the 2023 Tandem
Meetings. Watch the MM experts clarify the most recent
practice-changing evidence with BCMA-directed treatments and hear
them provide insight on rapidly emerging future applications.
Throughout, the experts deliver take-homes on the selection and
sequential use of BCMA options, their use in earlier lines of
therapy, and management of unique safety considerations. Get
informed and see if you are hitting the target when it comes to
your patients with MM! Upon completion of this activity,
participants should be better able to: Summarize new and emerging
evidence with novel BCMA-targeting platforms, including ADCs,
bispecifics, and CAR-T cell therapy, across several lines of
treatment in MM; Apply evidence-based treatment plans with
BCMA-targeting platforms for the sequential management of patients
with MM; and Utilize proven tools to address practical aspects and
safety considerations associated with the use of novel
BCMA-targeted platforms, including dosing, scheduling, adherence,
and AE management